Prof. A. Surolia, NII, New Delhi / IISc, Bangalore

 Dr. Ajay Saxena, SLS, JNU, New Delhi

 Dr. Amit Sharma, ICGEB, New Delhi

 Dr. Anil Saxena, CDRI, Lucknow

 Dr. Aparup Das, NMRI, New Delhi

 Dr. Asif Mohammad, ICGEB, New Delhi

 Dr. Chetan Chitinis, ICGEB, New Delhi

 Dr. Dinesh Gupta, ICGEB, New Delhi

 Dr. Dhanasekaran Shanmugam, NCL, Pune

 Dr. Hema Balaram , JNCASR, Bangalore

  Dr. P. V. Bharatam, NIPER, Mohali

 Dr. Pawan Malhotra, ICGEB, New Delhi

 Dr. Pushkar Sharma, NII, New Delhi

 Dr. Suman Dhar, SCMM, JNU, New Delhi

 Dr. Swati Patanikar, IIT Bombay

 Dr. Utpal Tatu, IISc, Bangalore

 Dr. V.Balasubramanian, AstraZeneca, Bangalore

 Prof. V.S.Chauhan, ICGEB, New Delhi

 Prof. Y.D.Sharma, AIIMS, New Delhi


Designed & Developed by Sudhir Patwal, spatwal@mail.jnu.ac.in | Copyright © 2012, Jawaharlal Nehru University, New Delhi.
Convener(s) Prof. Indira Ghosh SC&IS Jawaharlal Nehru University, New Delhi   Dr. Naidu Subbarao Dr. Dinesh Gupta SC&IS ICGEB Jawaharlal Nehru University New Delhi New Delhi  All correspondence for the workshop should be addressed to :  Dr. Naidu Subbarao School of Computational and Integrative Sciences Hall No. 6, Lecture Hall Complex Jawaharlal Nehru University New JNU Campus, New Delhi Email:nsrao@mail.jnu.ac.in

Malaria is the fifth cause of death from infectious diseases worldwide (after respiratory infections, HIV/AIDS,diarrheal diseases, and tuberculosis) and the second in Africa, after HIV/AIDS. It is caused by unicellular, protozoan parasites of the genus Plasmodium. About 41% of the world's population lives in areas where malaria is transmitted (e.g., parts of Africa, Asia, the Middle East, Central and South America, Hispaniola, and Oceania) (WHO: http://www.who.int/mediacentre/factsheets/). The serious problem of malaria parasite is drug resistance to currently used antimalarials has led to an urgent need to develop new and effective antimalarial molecules. There are 10 main groups of antimalarial drugs in use. Most of these drugs are primarily active against the blood forms of the parasite. Prior to the Second World War, Quinine, Primaquine, ChloroQuine and Mepacrine were developed. These were followed by Proguanil and AtovaQuone (in the 1940s), Primaquine and Pyrimethamine (1950s), Sulfadooxine/Pyrimethamine (1960s), Artemisinin (1970s, in China) and then a spurt of drugs in the 1980s:

MefloQuine, Halofantrine and various Chinese compounds - Pyronaridine (PRN), Piperaquine (PPQ) and the Artemisinin derivatives-Artemether, Artesunate and Dihydroartemisinin (DHA). Parasite resistance to the new agents by combination therapy may be reduced and highly effective. The concept of combination therapy is based on the synergistic or additive potential of two or more drugs, to improve therapeutic efficacy and also delay the development of resistance to the individual components of the combination. A safe and effective vaccine would have been the easiest way to control this disease, but even after decades of search, that vaccine is still elusive. It is due to the complex life cycle of the parasite involving human and vector mosquitoes as well as its allergic diversity and antigenic variations make the development and implementation of effective malaria control intervention problematic.



The workshop will cover the following topics


 Malaria Genomics/Proteomics

 Malaria Vaccine Development

 Current scenario of Malaria Drug Development

 Drug Target Validation and Proritization

 Structural Bioinformatcs/chemoinformatics

 Malaria Drug Target Database Development

 Target  Based Drug Designing

 Target-drug interaction mapping

 3DQSAR and Pharmacophore Design

 Antimalarial Database Development


sponsored by MCIT, Govt of India.

Jointly Organized by 






Jointly organized by